Cataract surgery in diabetic retinopathy

Intravitreal Triamcinolone vs Intravitreal Bevacizumab

Intravitreal bevacizumab and triamcinolone acetonide had decreased progression of diabetic retinopathy compared to previous studies where no adjunctive treatment was administered.(DiMECat, 2020). {Sasongko MB, Rogers S, Constantinou M, Sandhu SS, Wickremasinghe SS, Al-Qureshi S, Lim LL. Diabetic retinopathy progression 6 months post-cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial. Clin Exp Ophthalmol. 2020 Aug;48(6):793-801.}

Subconjunctival Triamcinolone vs Intravitreal Bevacizumab

Diabetic patients who received subconjunctival triamcinolone at the end of cataract surgery had a lower macular thickness and volume at six and 12 weeks postoperatively than patients who did not. Intravitreal bevacizumab had no significant effect.(PREMED, 2018). {Wielders LHP, Schouten JSAG, Winkens B, van den Biggelaar FJHM, Veldhuizen CA, Murta JCN, Goslings WRO, Kohnen T, Tassignon MJ, Joosse MV, Henry YP, Nagy ZZ, Rulo AHF, Findl O, Amon M, Nuijts RMMA; ESCRS PREMED study group. Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2. J Cataract Refract Surg. 2018 Jul;44(7):836-847.}